Short-Term Risedronate Treatment in Postmenopausal Women: Effects on Biochemical Markers of Bone Turnover

Abstract

The development of new biochemical markers has made it possible to assess the effects of therapeutic agents on bone turnover more rapidly and precisely. In this early phase II study, we analyzed the effects of short-term, high-dose treatment with risedronate, a potent pyridinyl bisphosphonate, on markers of bone resorption and formation. Resorption markers included urinary free deoxypyridinoline (D-Pyr) crosslinks, N-terminal telopeptide (NTx) and C-terminal telopeptide (CTx) type I collagen crosslinks. Bone formation markers included osteocalcin (OC), bone-specific alkaline phosphatase (BSAP) and the C-terminal peptide of type I procollagen (PICP). All three resorption markers showed rapid, significant (p<0.05) decreases from baseline following daily administration of 30 mg risedronate for 2 weeks. The mean decreases at 2 weeks were 28% for D-Pyr, 61% for NTx and 73% for CTx, respectively. Over the next 10 weeks after treatment, D-Pyr approached baseline while NTx and CTx remained well below baseline values. The markers of bone formation showed little change during therapy but decreased significantly at 4-10 weeks after therapy - an expected outcome of bisphosphonate therapy. Moreover, there was a significant correlation between the early effects on bone resorption markers and the delayed effects on formation markers. This study demonstrates that the approved dose of risedonate (30 mg/day) for Paget's disease is effective at decreasing bone turnover after 2 weeks of treatment, as observed by the sensitive response of bone turnover markers.

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression

“…Treatment with once-monthly ibandronate significantly reduced median serum CTX-I within 3 days of treatment initiation. Though prior studies have found clinically relevant changes in markers of bone resorption within 7 days of bisphosphonate initiation [5,15], this study demonstrates that significant changes in serum CTX-I levels are evident as early as 3 days after ibandronate administration. We also observed reductions in bone ALP levels.…”

“…Many bisphosphonate clinical trials have examined changes in BTMs at intervals of 1-3 months or longer [7,12,14], but recent studies find significant changes in BTMs from baseline within the first few weeks of therapy [5,6,15]. Monthly ibandronate was recently found to reduce serum CTX-I by 70% 7 days after administration [5].…”

Relationship Between Ageing and Bone Turnover Markers in Periodontal Disease

“…Bu biyokimyasal markırlar, kemik yapımının ve yıkımının izlenmesinde kullanılmaktadır 22 . Kemik yapım ve yıkımının biyokimyasal markırları dolaylı yoldan kemik kaybının hızı hakkında fikir vermekte ve böylece osteoporöz gibi metabolik kemik hastalıklarının risk tayininde, tedavi seçiminde ve tedavinin etkinliğinin değerlendirilmesinde fayda sağlamaktadırlar 23 . Yakın zamanda yapılan çalışmalarda bu markırların kemik turnover hızındaki anomalileri tespit etmekte kullanılan geleneksel tetkiklere göre çok daha fazla duyarlı oldukları bildirilmiştir.…”

The Effects of Whole Body Vibration Training on Some Biochemical Values in Terms of Osteoporosis Risk in Premenopausal Women

“…To determine bone loss velocity, Osteocalcin and CTx are mostly used as bone cycle indicators. One of the markers of bone turnover speed in blood is Osteocalcin, and of the bone destruction is CTx (Raisz et al 2000;Koç et al 2004). The aim of this study is to comparatively examine the effects of Whole body vibration (WBV) trainings on some biochemical values (Beta-CTx, Osteocalcin).…”